Evidence map›Paper›PMID 39780907›Full record

ArticleClinical case reports2025

EML4-ALK-Positive Ovarian Cancer With Intracranial Metastasis Responds to Lorlatinib: A Case Report and Literature Review.

Qiongqian Li, Tongze Cai, Xiaoming Zheng, Shunrong Zhang, Chanjuan Li, Huang Tang, Zhiyong Yu, Jianlong Zhou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Qiongqian LiDepartment of Oncology Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine Guangxi China.
Tongze CaiDepartment of Oncology Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine Guangxi China.
Xiaoming ZhengDepartment of Oncology Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine Guangxi China.
Shunrong ZhangDepartment of Oncology Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine Guangxi China.
Chanjuan LiDepartment of Oncology Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine Guangxi China.
Huang TangDepartment of Oncology Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine Guangxi China.
Zhiyong YuDepartment of Oncology Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine Guangxi China.
Jianlong ZhouDepartment of Oncology Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine Guangxi China.ORCID https://orcid.org/0009-0003-1910-3480

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a case showing that lorlatinib is effective in treating EML4-ALK-positive low-grade serous ovarian cancer (LGSO) with intracranial metastasis. This may be the first clinical evidence of LGSO benefit from ALK inhibitors, to provide evidence for the use of ALK inhibitors in more ovarian cancer patients with EML4-ALK fusion and promoting new ideas for the study of EML4-ALK targets in ovarian cancer.

Indexed as

EML4‐ALK fusion geneintracranial metastasislorlatinibovarian cancer

Identifiers

PMID39780907
PMCPMC11707256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.